RECRUITING

A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)

Conditions

Complicated Intra-abdominal Infections (cIAI)Complicated Intra-abdominal Infections cIAI eravacycline

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

A Phase 2 trial to assess safety, tolerability, and pharmacokinetics of eravacycline in pediatric patients aged 8 to \<18 years with cIAI.

Official Title

Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Intravenous Eravacycline in Pediatric Patients From 8 Years to Less Than 18 Years of Age With Complicated Intra-abdominal Infections (cIAI)

Quick Facts

Study Start:2025-05-22

Study Completion:2029-10-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06794541

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:8 Years to 17 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:CHILD

Inclusion Criteria	Exclusion Criteria
1. Children from 8 to \<18 years of age (as of the day of the informed consent \[and assent, if applicable\] is obtained), hospitalized for cIAI with one of the following diagnoses: 1. Intra-abdominal abscess (including hepatic and splenic abscesses). 2. Gastric or intestinal perforation associated with diffuse peritonitis. 3. Peritonitis: diffuse infection of the peritoneum (but not spontaneous bacterial peritonitis associated with cirrhosis and chronic ascites). 4. Appendicitis with perforation, peritonitis, or abscess (complicated appendicitis). 5. Cholecystitis with perforation or abscess. 2. Patient has evidence of age-appropriate abnormal systemic inflammatory response syndrome 3. Written informed consent from parent(s) or other legally authorized representative(s) and assent (according to local requirements). 4. In the investigator's opinion, the patient will require hospitalization for at least 4 days. 5. The patient must require hospitalization initially and antibacterial therapy for 4 to 14 days in addition to surgical intervention for the treatment of the current cIAI based on the judgment of the investigator. 6. The patient has sufficient intravascular access (peripheral or central) to receive eravacycline. 7. The patient meets either (A or B) of the following criteria: 1. Pre-operative enrollment: * i. Has a sonogram or radiographic imaging result consistent with the diagnosis of cIAI, and * ii. Acute surgical or percutaneous intervention (open laparotomy, laparoscopic surgery, or percutaneous drainage of an abscess) is foreseen within 24 hours. 2. Intra-operative/postoperative enrollment: * i. Visual confirmation of cIAI (presence of pus within the abdominal cavity), and * ii. Surgical intervention includes open laparotomy, laparoscopic surgery, or percutaneous draining of an abscess, and * iii. Intervention is considered adequate by the surgical team.	1. Patient is considered by the investigator to be unlikely to survive the trial period, and/or has any rapidly progressing disease or immediately life-threatening illness. 2. Patient's laboratory test results reveal alanine aminotransferase or aspartate transaminase \>5×upper limit of normal range (ULN). 3. Patient's laboratory test results reveal total bilirubin \>2×ULN, unless isolated hyperbilirubinemia is directly related to the acute process. 4. Patient requires peritoneal dialysis, hemodialysis, or hemofiltration at screening. Patient has an estimated glomerular filtration rate (eGFR) \<50 mL/minute/1.73 m². 5. Patient has previously received eravacycline or have enrolled previously in the current trial and been discontinued. 6. Patient has evidence or history of a clinically significant medical condition that may, in the opinion of the investigator, impair trial participation or pose a significant safety risk or diminish the patient's availability to undergo all trial procedures and assessments. 7. Patient is likely to require more than 14 days of treatment with eravacycline, in the opinion of the investigator. 8. Patient is currently participating in or has participated in an interventional clinical trial with an investigational compound or device within 30 days or \<5 half-lives of the eravacycline (whichever is longer) prior to screening. 9. Patient has immunocompromised condition, including acquired immune deficiency syndrome (AIDS), organ (including bone marrow) transplant recipients, and hematologic malignancy, or receiving immunosuppressive therapy, including cancer chemotherapy, medications for prevention of organ transplantation rejection, or chronic administration of systemic corticosteroids (defined as the systemic equivalent of ≥2 mg/kg total daily dose of prednisone for patients ≤20 kg, or \>40 mg of prednisone per day for patients \>20 kg, administered continuously for more than 14 days in the 30 days prior to the first dose of eravacycline. 10. Patient has known or suspected inflammatory bowel disease. 11. Patient has pancreatitis. 12. Patient has systemic malignancy that required chemotherapy, immunotherapy, radiation therapy, or antineoplastic therapy within the previous 3 months. 13. Patient has history of hypersensitivity or allergic reaction to any tetracycline antibiotics. 14. Patient has cIAI caused by a pathogen(s) resistant to eravacycline at screening. 15. Patient has received antibacterial drug therapy for continuous duration of \>72 hours immediately preceding screening unless they are considered treatment failures. Note: Treatment failure is defined as persistent fever and/or clinical symptoms or the development of a new intra-abdominal abscess after ≥72 hours of antibiotic therapy. 16. Patient has received any tetracycline within 14 days of screening. 17. Patient used cytochrome P450 (CYP) 3A inducers or inhibitors within 14 days of screening or is receiving or anticipated to need treatment with CYP3A inducers or inhibitors during the treatment period. 18. Patient used inducers and/or inhibitors of P-glycoprotein (P-gp), organic anion transporting polypeptide (OATP)1B1, and OATP1B3 transporters within 14 days of screening or is receiving or anticipated to need treatment such agents during the treatment period. 19. Patient is currently using or anticipates use of anticoagulant therapy during the treatment period. 20. Patient is unable or unwilling, in the opinion of the investigator, to comply with the protocol. 21. Patients who are known to be pregnant (positive pregnancy test) and/or breastfeeding at the time of screening. 22. Sexually active patients of childbearing potential (those with menarche and/or thelarche) who are unwilling or unable to use an acceptable method of contraception (at least 2 medically accepted, effective methods of birth control \[e.g., condom, oral contraceptive, indwelling intrauterine device, hormonal implant/patch, injections, approved cervical ring\]) or sexual abstinence. 23. Patient has any other circumstance that, in the opinion of the investigator, precludes the patient's participation in the trial.

Inclusion Criteria

Exclusion Criteria

1. Children from 8 to \<18 years of age (as of the day of the informed consent \[and assent, if applicable\] is obtained), hospitalized for cIAI with one of the following diagnoses:
1. Intra-abdominal abscess (including hepatic and splenic abscesses).
2. Gastric or intestinal perforation associated with diffuse peritonitis.
3. Peritonitis: diffuse infection of the peritoneum (but not spontaneous bacterial peritonitis associated with cirrhosis and chronic ascites).
4. Appendicitis with perforation, peritonitis, or abscess (complicated appendicitis).
5. Cholecystitis with perforation or abscess.
2. Patient has evidence of age-appropriate abnormal systemic inflammatory response syndrome
3. Written informed consent from parent(s) or other legally authorized representative(s) and assent (according to local requirements).
4. In the investigator's opinion, the patient will require hospitalization for at least 4 days.
5. The patient must require hospitalization initially and antibacterial therapy for 4 to 14 days in addition to surgical intervention for the treatment of the current cIAI based on the judgment of the investigator.
6. The patient has sufficient intravascular access (peripheral or central) to receive eravacycline.
7. The patient meets either (A or B) of the following criteria:
1. Pre-operative enrollment:
* i. Has a sonogram or radiographic imaging result consistent with the diagnosis of cIAI, and
* ii. Acute surgical or percutaneous intervention (open laparotomy, laparoscopic surgery, or percutaneous drainage of an abscess) is foreseen within 24 hours.
2. Intra-operative/postoperative enrollment:
* i. Visual confirmation of cIAI (presence of pus within the abdominal cavity), and
* ii. Surgical intervention includes open laparotomy, laparoscopic surgery, or percutaneous draining of an abscess, and
* iii. Intervention is considered adequate by the surgical team.

1. Patient is considered by the investigator to be unlikely to survive the trial period, and/or has any rapidly progressing disease or immediately life-threatening illness.
2. Patient's laboratory test results reveal alanine aminotransferase or aspartate transaminase \>5×upper limit of normal range (ULN).
3. Patient's laboratory test results reveal total bilirubin \>2×ULN, unless isolated hyperbilirubinemia is directly related to the acute process.
4. Patient requires peritoneal dialysis, hemodialysis, or hemofiltration at screening. Patient has an estimated glomerular filtration rate (eGFR) \<50 mL/minute/1.73 m².
5. Patient has previously received eravacycline or have enrolled previously in the current trial and been discontinued.
6. Patient has evidence or history of a clinically significant medical condition that may, in the opinion of the investigator, impair trial participation or pose a significant safety risk or diminish the patient's availability to undergo all trial procedures and assessments.
7. Patient is likely to require more than 14 days of treatment with eravacycline, in the opinion of the investigator.
8. Patient is currently participating in or has participated in an interventional clinical trial with an investigational compound or device within 30 days or \<5 half-lives of the eravacycline (whichever is longer) prior to screening.
9. Patient has immunocompromised condition, including acquired immune deficiency syndrome (AIDS), organ (including bone marrow) transplant recipients, and hematologic malignancy, or receiving immunosuppressive therapy, including cancer chemotherapy, medications for prevention of organ transplantation rejection, or chronic administration of systemic corticosteroids (defined as the systemic equivalent of ≥2 mg/kg total daily dose of prednisone for patients ≤20 kg, or \>40 mg of prednisone per day for patients \>20 kg, administered continuously for more than 14 days in the 30 days prior to the first dose of eravacycline.
10. Patient has known or suspected inflammatory bowel disease.
11. Patient has pancreatitis.
12. Patient has systemic malignancy that required chemotherapy, immunotherapy, radiation therapy, or antineoplastic therapy within the previous 3 months.
13. Patient has history of hypersensitivity or allergic reaction to any tetracycline antibiotics.
14. Patient has cIAI caused by a pathogen(s) resistant to eravacycline at screening.
15. Patient has received antibacterial drug therapy for continuous duration of \>72 hours immediately preceding screening unless they are considered treatment failures. Note: Treatment failure is defined as persistent fever and/or clinical symptoms or the development of a new intra-abdominal abscess after ≥72 hours of antibiotic therapy.
16. Patient has received any tetracycline within 14 days of screening.
17. Patient used cytochrome P450 (CYP) 3A inducers or inhibitors within 14 days of screening or is receiving or anticipated to need treatment with CYP3A inducers or inhibitors during the treatment period.
18. Patient used inducers and/or inhibitors of P-glycoprotein (P-gp), organic anion transporting polypeptide (OATP)1B1, and OATP1B3 transporters within 14 days of screening or is receiving or anticipated to need treatment such agents during the treatment period.
19. Patient is currently using or anticipates use of anticoagulant therapy during the treatment period.
20. Patient is unable or unwilling, in the opinion of the investigator, to comply with the protocol.
21. Patients who are known to be pregnant (positive pregnancy test) and/or breastfeeding at the time of screening.
22. Sexually active patients of childbearing potential (those with menarche and/or thelarche) who are unwilling or unable to use an acceptable method of contraception (at least 2 medically accepted, effective methods of birth control \[e.g., condom, oral contraceptive, indwelling intrauterine device, hormonal implant/patch, injections, approved cervical ring\]) or sexual abstinence.
23. Patient has any other circumstance that, in the opinion of the investigator, precludes the patient's participation in the trial.

Contacts and Locations

Study Contact

ISTX Clinical Trials

CONTACT

617-715-3600

clinicaltrials@istx.com

Study Locations (Sites)

Children's Hospital of Orange County

Orange, California, 92868

United States

Ann and Robert H Lurie Children's Hospital of Chicago

Chicago, Illinois, 60611

United States

Children's Hospital of LSU Health Sciences Center Shreveport

Shreveport, Louisiana, 71101

United States

West Virginia University Medicine Children's Hospital

Morgantown, West Virginia, 26506

United States

Collaborators and Investigators

Sponsor: Innoviva Specialty Therapeutics

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-05-22

Study Completion Date2029-10-31

Study Record Updates

Study Start Date2025-05-22

Study Completion Date2029-10-31

Terms related to this study

Keywords Provided by Researchers

Complicated Intra-abdominal Infections
cIAI
eravacycline

Additional Relevant MeSH Terms

Complicated Intra-abdominal Infections (cIAI)